Regdanvimab improves disease mortality and morbidity in patients with COVID-19: A meta-analysis

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

(2022) Laura A. VanBlargan et al.   NATURE MEDICINE

Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients with Mild-to-Moderate Coronavirus Disease 2019

(2022) Anca Streinu-Cercel et al.   Open Forum Infectious Diseases

Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score–matched retrospective cohort study

(2022) Shinwon Lee et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

The effect of canakinumab on clinical outcomes in patients with COVID-19: A meta-analysis

(2022) Guangyu Ao et al.   JOURNAL OF INFECTION

Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19

(2022) Taeyun Kim et al.   Journal of Clinical Medicine

Regdanvimab: First Approval

(2021) Yahiya Y. Syed   DRUGS

Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease

(2021) Ji Yeon Lee et al.   Frontiers in Immunology